| Patient | Booker T. Washington |
|---|---|
| Date of birth | 1967-04-05 |
| Identifiers | MRN HR-NI017-SYN; SSN (made up) 000-17-2284 |
| Document date | 2026-10-26 |
| Author | Lorraine Whitfield, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-month blood pressure and chronic kidney disease review. [S]
Mr. Washington returns for his six-month review. The back strain in August cleared in about ten days, and he has taken no NSAIDs since. His home readings run in the high 110s to low 120s systolic, with no dizziness on standing. His headaches have not returned, and his concentration is better than in the spring, though he still tires by evening on travel days. He walks 20 to 30 minutes on most days at home. He gets up once a night to urinate and has had no genital symptoms on dapagliflozin. He received the influenza and first zoster vaccines last month. He asked last month to learn more about what would happen if his kidney function fell further. [S]
| Element | Detail |
|---|---|
| Interval history | August back strain resolved; no NSAIDs since |
| Home blood pressure | High 110s to low 120s systolic; no dizziness |
| Symptoms | No headaches; concentration better; tires on travel days |
| Activity | Walking 20 to 30 minutes on most days |
| Patient question | What happens if his kidney function falls further |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tires by evening on travel days; weight stable |
| Eyes | Negative | No new blurring or loss of vision |
| Cardiovascular | Negative | No chest pain, palpitations, or ankle swelling |
| Genitourinary | Negative | Up once a night; no dysuria or genital symptoms |
| Musculoskeletal | Negative | Back pain resolved |
| Neurological | Negative | No headache or dizziness on standing |
| Psychiatric | Negative | Mood steady; PHQ-9 score 2 |
7 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Amlodipine 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-05-04 | active | S |
| Losartan 50 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-05-04 to 2026-05-11 | completed | S |
| Losartan 100 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-05-11 | active | S |
| Dapagliflozin 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-05-11 | active | S |
| Chlorthalidone 25 mg oral tablet, one-half tablet (12.5 mg) by mouth daily | One-half tablet by mouth daily | Oral route | 2026-06-01 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-05-04 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-26 | Body height | 170 | cm | S |
| 2026-10-26 | Body weight | 70.5 | kg | S |
| 2026-10-26 | Body mass index (BMI) [Ratio] | 24.4 | kg/m2 | S |
| 2026-10-26 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-10-26 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-10-26 | Heart rate | 72 | /min | S |
| 2026-10-26 | Respiratory rate | 14 | /min | S |
| 2026-10-26 | Body temperature | 36.6 | Cel | S |
| 2026-10-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-26 | Sodium [Moles/volume] in Serum or Plasma | 136 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-10-26 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-10-26 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 23 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-10-26 | Urea nitrogen [Mass/volume] in Serum or Plasma | 34 | mg/dL | 6-24 mg/dL | High | S |
| 2026-10-26 | Creatinine [Mass/volume] in Serum or Plasma | 2.3 | mg/dL | 0.74-1.35 mg/dL | High | S |
| 2026-10-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 32 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 2026-10-26 | Glucose [Mass/volume] in Serum or Plasma | 93 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-10-26 | Calcium [Mass/volume] in Serum or Plasma | 9.2 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-10-26 | Phosphate [Mass/volume] in Serum or Plasma | 4 | mg/dL | 2.5-4.5 mg/dL | Normal | S |
| 2026-10-26 | Parathyrin.intact [Mass/volume] in Serum or Plasma | 78 | pg/mL | 15-65 pg/mL | High | S |
| 2026-10-26 | Hemoglobin [Mass/volume] in Blood | 12.8 | g/dL | 13.2-16.6 g/dL | Low | S |
| 2026-10-26 | Albumin/Creatinine [Mass Ratio] in Urine | 240 | mg/g | <=30 mg/g | High | S |
| 2026-10-26 | Kidney failure 2-year risk [Likelihood] by KFRE | 6.5 | % | S | ||
| 2026-10-26 | Kidney failure 5-year risk [Likelihood] by KFRE | 18.8 | % | S | ||
| 2026-10-26 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | S |
Vital signs recorded on 2026-10-26; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well |
| Blood pressure | 118/76 mmHg, the average of two seated readings after five minutes' rest; no fall on standing |
| Heart | Regular rhythm, rate 72; soft S4 |
| Lungs | Clear |
| Extremities | No edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Severe hypertension with hypertensive kidney disease; synthetic modern diagnosis linked to the documented 1915 blood pressure of 220/150 | active | confirmed | I12.9 | S — Synthetic active diagnosis for the teaching episode; the 1915 findings remain D and the retrospective diagnosis remains R. |
| Chronic kidney disease stage G3b A3 (severely increased albuminuria), attributed to hypertensive nephrosclerosis | active | confirmed | N18.32 | S — Synthetic diagnosis supported by small echogenic kidneys and albuminuria; linked to the documented 1915 diagnosis of Bright's disease. |
| Hypertensive retinopathy, both eyes, without papilledema | active | confirmed | H35.033 | S — Synthetic funduscopic finding that echoes the documented failing vision. |
| Mild anemia of chronic kidney disease, iron replete; monitor | active | confirmed | D63.1 | S — Synthetic finding from the baseline hemoglobin and iron studies. |
| Hyperlipidemia | active | confirmed | E78.5 | S — Synthetic finding from the baseline LDL cholesterol. |
| Acute lumbar muscle strain after lifting, resolved without NSAIDs or imaging | resolved | confirmed | S39.012A | S — Synthetic intercurrent illness at an unscheduled visit; it does not echo a documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Basic metabolic panel | With each eGFR draw | Completed today | Potassium 4.5, bicarbonate 23, creatinine 2.3 mg/dL, eGFR 32 |
| Laboratory | eGFR and urine albumin-creatinine ratio | About 3 times a year for G3b A3 | Completed today | eGFR 32; urine albumin-creatinine ratio 240 mg/g, down 71 percent from 820. The third pair since diagnosis, on schedule |
| Laboratory | Calcium, phosphate, and PTH | Every 6 to 12 months in G3b | Completed today | Calcium 9.2, phosphate 4.0, PTH 78 pg/mL (down from 92) |
| Laboratory | 25-hydroxyvitamin D | Once at baseline | Deferred | Not drawn at diagnosis or with today's calcium, phosphate, and PTH, a deviation from the protocol. PTH is falling with normal calcium and phosphate, so no harm is evident. Corrective action: added to the next draw |
| Laboratory | Hemoglobin | At least yearly in G3 | Completed today | 12.8 g/dL, stable |
| Laboratory | Iron studies | At anemia diagnosis; repeat with a fall in hemoglobin or on an ESA | Not indicated | Iron replete in May; hemoglobin stable and no ESA |
| Survey | Kidney failure risk equation, 2 and 5 years | Yearly in G3 to G5 | Completed today | 6.5 percent at 2 years and 18.8 percent at 5 years; the 5-year risk is above the 3 to 5 percent referral threshold, confirming nephrology care |
| Referral | Nephrology | 5-year kidney failure risk of 3 to 5 percent or more, or persistent A3 albuminuria | Up to date | Seen in May; today's results, risk scores, and his question about kidney failure options sent ahead of his next nephrology review |
| Laboratory | Urinalysis with microscopy | With a change in status | Not indicated | No change in status: albuminuria fell by 71 percent and eGFR is stable. The missing baseline urinalysis is recorded as a deviation at the one-week visit |
| Laboratory | Cystatin C | When a decision hinges on a more accurate eGFR | Not indicated | No dosing or referral decision depends on it now |
| Laboratory | Alkaline phosphatase | Yearly in G4 to G5 | Not indicated | eGFR 32 is stage G3b |
| Laboratory | Lipid panel | Once at diagnosis in chronic kidney disease; yearly when stable in the lipid monograph | Not indicated | No repeat LDL, per the CKD monograph and KDIGO; a deliberate departure from the lipid monograph |
| Laboratory | HbA1c | Yearly in hypertension | Up to date | 5.4 percent in May; glucose 93 mg/dL today |
| Examination | Standardized office blood pressure | Every visit; target systolic below 120 when tolerated | Completed today | 118/76 mmHg; systolic target met |
| Examination | Weight, BMI, and cardiac auscultation | Every visit | Completed today | 70.5 kg, BMI 24.4; soft S4 |
| Examination | Funduscopic examination | Yearly in chronic hypertension | Up to date | Dilated examination in May; unchanged on undilated examination last month; next in May |
| Imaging | ECG and echocardiogram | At diagnosis; repeat as clinically indicated | Not indicated | Left ventricular hypertrophy documented in May; no new symptoms |
| Examination | Peripheral pulses and ankle-brachial index | Every 2 to 3 years at 65 or older or with a smoking history | Not indicated | Age 59 and a never smoker |
| Survey | 10-year ASCVD risk estimate | Yearly in hypertension | Not indicated | Already on a statin for the chronic kidney disease indication, so the estimate would not change treatment |
| Survey | PHQ-9 | Yearly in hypertension | Completed today | Score 2 |
| Medication safety | Medication review: NSAID avoidance and kidney dosing | Every visit | Completed today | No NSAIDs since the August naproxen; the pharmacy flag is in place |
| Medication safety | Vaccination review | Yearly in chronic kidney disease | Due | Influenza and zoster dose 1 given last month; zoster dose 2 due from next month; COVID-19 and RSV vaccines were discussed last month |
| Self-management | Home blood pressure log, sodium below 2 g a day, and activity | Every visit | Completed today | Walking about 120 minutes a week; goal 150. Sodium plan for travel reinforced |
Goal progress:
Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); CMID: Clinical Monitoring Intelligence Database, hypertension and chronic kidney disease monographs (2026)
Follow-up: PSA and hepatitis C and HIV screening from the preventive plan added to today's draw; results reviewed when they return. Zoster vaccine dose 2 from next month. Blood pressure and kidney review in about four months with eGFR, urine albumin, a basic metabolic panel, and vitamin D. Nephrology review. [S]